The Singapore Exchange just made its most aggressive move yet to dominate Asia’s derivatives market. SGX signed a new licensing agreement with MSCI Inc. that will bring up to 100 new futures and options contracts to the exchange, covering everything from global developed-market benchmarks to sector-specific indexes across Emerging Market Asia.

The initial phase alone will roll out roughly 40 contracts.

What the deal actually covers

The new contracts will span three broad categories: global developed-market benchmarks, Asia-Pacific single-country indexes, and Emerging Market Asia sector indexes. That’s a meaningful expansion from SGX’s existing MSCI product suite, which has historically focused on core Asian exposures.

SGX CEO Loh Boon Chye framed the expansion as building a comprehensive MSCI suite that empowers investors to navigate global equity risks from a single venue. MSCI CEO Henry Fernandez echoed that sentiment, noting the deal would significantly boost access to MSCI’s benchmarks for institutional investors.

The timing isn’t accidental. SGX reported record liquidity in its equity derivatives markets during 2025, which gave the exchange both the confidence and the mandate to push further.

What this means for investors

For institutional investors, the immediate benefit is consolidation. Managing derivatives positions across multiple exchanges creates operational complexity, margin fragmentation, and counterparty risk. A single venue offering broad MSCI coverage simplifies all of that.

The record liquidity SGX saw in 2025 suggests that market participants are already comfortable with the exchange’s infrastructure and clearing capabilities. Adding new contracts to an already liquid venue means those products are more likely to achieve viable trading volumes quickly, rather than languishing with wide bid-ask spreads.